Please login to the form below

Not currently logged in
Email:
Password:

Elite Pharma names Actavis VP as CEO

Nasrat Hakim also has senior experience at Watson and Alpharma

Nasrat Hakim, Elite Nasrat Hakim has left his international VP position at Actavis to join Elite Pharmaceuticals as president and CEO.

The move was announced alongside the news that Elite has purchased multiple products from Mikah Pharma – a pharma company founded by Hakim in 2009.

These include 12 generic drugs already approved by the US Food and Drug Administration (FDA) but are yet to be marketed. An additional generic product is under review.

“Nasrat has broad experience in both branded and generic pharmaceuticals as well as extensive regulatory experience and I have tremendous confidence in his ability to drive operational excellence and growth as we advance the development of products utilising our proprietary abuse resistant technology,” said Elite's chairman Jerry Treppel.

“The acquisition of the Mikah products is expected to eventually significantly enhance our revenue base over time with a commensurate increase in cash flow that will be utilised to decrease our operating losses and then support R&D.”

Hakim was most recently international vice president of quality assurance at Actavis having pervious service as corporate VP of technical services, quality and regulatory compliance for Actavis US.

His positions prior to Actavis include global VP, quality and regulatory compliance for Alpharma, as well as executive director of the quality unit at TheraTech.

7th August 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics